Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.28 AUD | 0.00% | +3.17% | -21.11% |
May. 28 | Ord Minnett Starts Australian Clinical Labs at Buy, Price Target is AU$3.50 | MT |
May. 21 | Australian Clinical Expects Fiscal 2024 Earnings to Fall at Lower End of Forecast | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company is in a robust financial situation considering its net cash and margin position.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.11% | 305M | C | ||
+23.03% | 87.14B | C+ | ||
-23.64% | 75.59B | B- | ||
+1.76% | 26.78B | C+ | ||
+3.99% | 17.89B | A- | ||
-14.44% | 16.44B | B | ||
+2.92% | 15.68B | A- | ||
+69.52% | 13.3B | C- | ||
+76.23% | 13.06B | C+ | ||
+3.11% | 12.54B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ACL Stock
- Ratings Australian Clinical Labs Limited